Obe-cel shows deep and durable responses in severe refractory lupus in Phase 1 CARLYSLE trial – Autolus
Autolus Therapeutics has presented longer-term follow-up data from the Phase 1 CARLYSLE trial of obecabtagene autoleucel (obe-cel) in severe refractory systemic lupus erythematosus (srSLE) in a poster session… read more.
